Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis
Status:
Not yet recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind randomized controlled study to assess the efficacy and
safety of Jinshuibao for patients with CKD due to glomerulonephritis, with a planned
follow-up of 48 weeks.